Secretory autophagy: a turn key for understanding AMD pathology and developing new therapeutic targets?
| Autor: | Janusz Blasiak, Kai Kaarniranta |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Expert Opinion on Therapeutic Targets. 26:883-895 |
| ISSN: | 1744-7631 1472-8222 |
| DOI: | 10.1080/14728222.2022.2157260 |
| Popis: | Age-related macular degeneration (AMD) is an eye disease leading to vision loss with poorly known pathogenesis and limited therapeutic options. Degradative autophagy (DA) is impaired in AMD, but emerging evidence points to secretary autophagy (SA) as a key element in AMD pathogenesis.SA may cause the release of proteins and protein aggregates, lipofuscin, beta amyloid, faulty mitochondria, pro-inflammatory and pro-angiogenic factors from the retinal pigment epithelium (RPE) that may contribute to drusen formation and choroidal neovascularization. SA may replace DA, when formation of autolysosome is impaired, and then a harmful cargo, instead of being degraded, is extruded from the RPE contributing to drusen and/or angiogenic environment. Therefore, the interplay between DA and SA may be critical for drusen formation and choroidal neovascularization, so it can be a turn key to understand AMD pathogenesis.Although SA fulfills some beneficial functions, it is detrimental for the retina in many cases. Therefore, inhibiting SA may be a therapeutic strategy in AMD, but it is challenged by the development of selective SA inhibitors that would not affect DA. The TRIM16, SEC22B and RAB8A proteins, specific for secretory autophagosome, may be primary candidates as therapeutic targets, but their action is not limited to autophagy and therefore requires further studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|